NDA 019855 · Aurobindo Pharma USA
Elimite
Permethrin · Topical · Pyrethroid
Last checked: Nov 20, 2026Latest source record: Feb 12, 2016 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1989
Aug 25, 1989
Approved uses
2
Original approval plus efficacy supplements
Registered trials
43
18 Phase 3, 1 recruiting
FAERS reports
1,358
690 serious, 58 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Mar 4, 2026.
INDICATIONS AND USAGE: Permethrin Cream, 5% is indicated for the treatment of infestation with Sarcoptes scabiei (scabies).
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 5, 1993 Supplement 1 · Efficacy
- Aug 25, 1989 Original approval · Type 3 - New Dosage Form
1 products under this application
- ELIMITE · PERMETHRIN 5% · CREAM, TOPICAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Permethrin" as an intervention, any sponsor and status, largest first.
- Better Options for Lymphatic Filariasis TreatmentPivotal-lookingRecruiting
Medicines Development for Global HealthAcademic, hospital or other
NCT07159373 · 5,100 participants (planned) · Start Sep 28, 2026 · Primary completion Jun 2027
Drug: MoxDA - Moxidectin + Diethylcarbamzine (DEC) + Albendazole; IDA - Ivermectin + DEC + albendazole · For: Lymphatic Filariasis; Scabies; Strongyloidiasis
Sites: Suva, Fiji
- Fiji Integrated Therapy (FIT) - Triple Therapy for Lymphatic Filariasis, Scabies and Soil Transmitted Helminths in FijiPivotal-lookingCompleted
Washington University School of MedicineAcademic, hospital or other
NCT03177993 · 4,773 participants · Start Jul 13, 2017 · Primary completion Nov 22, 2017
Drug: 3 drug dose - IDA; 3 drug dose - IDA with second dose of ivermectin and 1 more · For: Lymphatic Filariases; Scabies; Impetigo and 1 more
Sites: Suva, Fiji
- Azithromycin - Ivermectin Mass Drug Administration for Skin DiseasePivotal-lookingCompleted
London School of Hygiene and Tropical MedicineAcademic, hospital or other
NCT02775617 · 1,291 participants · Start Jul 2016 · Primary completion Aug 2017
Drug: Ivermectin; Azithromycin and 1 more · For: Scabies; Yaws; Impetigo
Sites: Atoifi, Solomon Islands
- Oral Ivermectin Versus Topical Permethrin to Treat Scabies in Children and AdultsPivotal-lookingCompleted
University Hospital, BordeauxAcademic, hospital or other
NCT02407782 · 1,092 participants · Start Jan 19, 2016 · Primary completion Dec 16, 2021
Drug: Ivermectin; Permethrin · For: Scabies
Sites: Bordeaux, France; Bron, France; Chalon-sur-Saône, France · 29 sites in all
Edward Via Virginia College of Osteopathic MedicineAcademic, hospital or other
NCT00604084 · 1,057 participants · Start May 2007 · Primary completion May 2008
Drug: Ivermectin; Permethrin 5% lotion · For: Scabies
Sites: Veron, Dominican Republic
- Malaria Elimination Pilot Study in Military Forces in CambodiaPivotal-lookingStatus unknown
Armed Forces Research Institute of Medical Sciences, ThailandGovernment (non-federal)
NCT02653898 · 1,050 participants · Start Jan 2016 · Primary completion Aug 2016
Drug: DHA-PIP; Primaquine and 2 more · For: Malaria; Parasitic Diseases
Sites: Anlong Veaeng, Cambodia
- Safety and Efficacy Study of NatrOVA Creme Rinse - 1% and NIX Creme Rinse in Subjects 6 Months or Older With Head LicePivotal-lookingCompleted
ParaPRO LLCIndustry
NCT00545753 · 558 participants · Start Sep 2007 · Primary completion Mar 2008
Drug: Spinosad; Spinosad and 1 more · For: Pediculosis
Sites: Scottsdale, Arizona; Hot Springs, Arkansas; Beverly Hills, California · 6 sites in all
- Safety and Efficacy Study of NatrOVA Creme Rinse - 1% and NIX Creme Rinse in Subjects 6 Months or Older With Head LicePivotal-lookingCompleted
ParaPRO LLCIndustry
NCT00545168 · 480 participants · Start Sep 2007 · Primary completion Mar 2008
Drug: Spinosad; Spinosad and 1 more · For: Pediculus Capitis Infestation
Sites: Ormond Beach, Florida; West Palm Beach, Florida; Indianapolis, Indiana · 6 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 11 |
| 2005 | 9 |
| 2006 | 7 |
| 2007 | 4 |
| 2008 | 5 |
| 2009 | 17 |
| 2010 | 28 |
| 2011 | 21 |
| 2012 | 29 |
| 2013 | 24 |
| 2014 | 33 |
| 2015 | 40 |
| 2016 | 84 |
| 2017 | 92 |
| 2018 | 137 |
| 2019 | 155 |
| 2020 | 141 |
| 2021 | 134 |
| 2022 | 80 |
| 2023 | 74 |
| 2024 | 98 |
| 2025 | 98 |
| 2026 | 37 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Scabies.
Johnstone PP, Strong M · BMJ Clin Evid 2008 · Systematic Review
- Failure of scabies treatment: a systematic review and meta-analysis.
Mbuagbaw L, Sadeghirad B, Morgan RL, et al. · Br J Dermatol 2024 · Meta-Analysis, Systematic Review
- Head lice.
Burgess IF · BMJ Clin Evid 2009 · Systematic Review
- Head lice.
Burgess IF · BMJ Clin Evid 2011 · Systematic Review
- House modifications for preventing malaria.
Fox T, Furnival-Adams J, Chaplin M, et al. · Cochrane Database Syst Rev 2022 · Research Support, Non-U.S. Gov't, Systematic Review
- Insect bite reactions.
Singh S, Mann BK · Indian J Dermatol Venereol Leprol 2013 · Systematic Review
Sponsor: Aurobindo Pharma USA
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.